Samantha Johnstone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Samantha Johnstone has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Tony Peter George
Department of Psychiatry, University of Toronto, Toronto, Canada
9 shared publications - Larry W. Hawk
Department of Psychology, University at Buffalo
5 shared publications David J. Castle
Centre for Complex Interventions and Addictions Division, Centre for Addiction and Mental Health, Toronto, Canada
4 shared publications- Maryam Sorkhou
Addictions Division Centre for Addiction and Mental Health (CAMH) Toronto Ontario Canada
4 shared publications - Hyoun Soo Kim
Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada
3 shared publications - Todd A. Girard
Toronto Metropolitan Univ, Dept Psychol, Toronto, ON, Canada
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Abstinence Expectancies in People who Smoke vs. Vape Nicotine: A Psychometric Comparison of the Smoking Abstinence Questionnaire and a Version Adapted for Vaping
Introduction: Abstinence outcome expectancies (AOEs), the anticipated consequences of drug cessation, predict key cessation outcomes such as withdrawal severity; however, the construct has yet to be extended to electronic nicotine delivery systems (ENDS). Methods: We conducted a psychometric evaluation the Smoking Abstinence Questionnaire (SAQ) and a parallel vaping adaptation. A multigroup confirmatory factor analysis was conducted to test measurement invariance across people who smoke (n = 126) or vape (n = 193) nicotine, and construct validity was assessed by examining associations between AOE domains and a measure of vaping dependence. Results: Results failed to support the original 10-factor structure of the SAQ; however, a modified 7-factor model demonstrated configural and metric invariance across nicotine product groups. Scalar invariance was not supported, as two items assessing the anticipated efficacy of nicotine replacement therapy and social benefits from quitting exhibiting noninvariant intercepts across groups. People who smoke reported higher latent mean scores for anticipated weight gain and changes in coffee consumption compared to people who vape. Further, the AOE domains demonstrated good internal consistencies and showed expected associations with vaping dependence. Conclusions: Findings suggest that AOEs function similarly across cigarette and ENDS use, while identifying item-level and latent mean expectancies that differ between product groups. Implications: This is the first study to extend the AOE construct to ENDS. Results suggest that many smoking-related abstinence expectancies extend to vaping, while some expectancies may differ by nicotine product.
- 6 November 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
Open AccessAbstinence Expectancies in People who Smoke vs. Vape Nicotine: A Psychometric Comparison of the Smoking Abstinence Questionnaire and a Version Adapted for Vaping
Introduction: Abstinence outcome expectancies (AOEs), the anticipated consequences of drug cessation, predict key cessation outcomes such as withdrawal severity; however, the construct has yet to be extended to electronic nicotine delivery systems (ENDS). Methods: We conducted a psychometric evaluation the Smoking Abstinence Questionnaire (SAQ) and a parallel vaping adaptation. A multigroup confirmatory factor analysis was conducted to test measurement invariance across people who smoke (n = 126) or vape (n = 193) nicotine, and construct validity was assessed by examining associations between AOE domains and a measure of vaping dependence. Results: Results failed to support the original 10-factor structure of the SAQ; however, a modified 7-factor model demonstrated configural and metric invariance across nicotine product groups. Scalar invariance was not supported, as two items assessing the anticipated efficacy of nicotine replacement therapy and social benefits from quitting exhibiting noninvariant intercepts across groups. People who smoke reported higher latent mean scores for anticipated weight gain and changes in coffee consumption compared to people who vape. Further, the AOE domains demonstrated good internal consistencies and showed expected associations with vaping dependence. Conclusions: Findings suggest that AOEs function similarly across cigarette and ENDS use, while identifying item-level and latent mean expectancies that differ between product groups. Implications: This is the first study to extend the AOE construct to ENDS. Results suggest that many smoking-related abstinence expectancies extend to vaping, while some expectancies may differ by nicotine product.
- Open Access
- 23 May 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28 (10) , 1635-1649
Birth outcomes following intrauterine exposure to electronic nicotine delivery systems: a systematic review and meta-analysis
Introduction: Despite electronic nicotine delivery systems (ENDS) being used for smoking cessation during pregnancy, the relative consequences are still unclear. Here, we systematically reviewed and meta-analyzed birth outcomes associated with ENDS use. Methods: This review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. OVID (MEDLINE, EMBASE, PsycINFO) and PubMed databases were searched from inception until August 2025, for studies comparing outcomes from in utero exclusive ENDS exposure to non-exposed, exclusive nicotine replacement therapy–exposed, or exclusive combustible cigarette (CC)–exposed neonates. Results: We included k = 22 studies with k = 10 independent samples. In ENDS-exposed vs non-exposed births, there were significantly greater odds of preterm birth (k = 3; moderate confidence) but not small for gestational age (SGA; k = 3; low confidence); these findings were less robust to sensitivity analysis. Additionally, there was no significant difference in SGA (k = 3; moderate confidence) or preterm birth (k = 3; high confidence) between CC-exposed and ENDS-exposed neonates; these findings were robust to sensitivity analysis. Analysis of continuous outcomes found lower birthweight in ENDS- vs non-exposed neonates (k = 4; moderate confidence) and lower birthweight in CC- vs ENDS-exposed neonates (k = 4; low confidence), and no difference in gestational age in either comparison (low confidence). Narrative synthesis suggests quitting ENDS was associated with better birth outcomes, and associations between ENDS and delayed development of infant motor maturity and reflexes. Conclusion: ENDS exposure may confer comparable risk as cigarette smoking to preterm birth. Further research is needed given low to moderate confidence in findings and risk of bias conferred by limited classification of exclusive ENDS use. Implications: With respect to adverse birth outcomes, ENDS may constitute a risk compared to no-nicotine exposure, suggesting the importance of investigating vaping cessation interventions, as well as greater research into alternative smoking cessation interventions for people who are pregnant or want to become pregnant.
- 23 May 2026
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28 (10) , 1635-1649
Open AccessBirth outcomes following intrauterine exposure to electronic nicotine delivery systems: a systematic review and meta-analysis
Introduction: Despite electronic nicotine delivery systems (ENDS) being used for smoking cessation during pregnancy, the relative consequences are still unclear. Here, we systematically reviewed and meta-analyzed birth outcomes associated with ENDS use. Methods: This review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. OVID (MEDLINE, EMBASE, PsycINFO) and PubMed databases were searched from inception until August 2025, for studies comparing outcomes from in utero exclusive ENDS exposure to non-exposed, exclusive nicotine replacement therapy–exposed, or exclusive combustible cigarette (CC)–exposed neonates. Results: We included k = 22 studies with k = 10 independent samples. In ENDS-exposed vs non-exposed births, there were significantly greater odds of preterm birth (k = 3; moderate confidence) but not small for gestational age (SGA; k = 3; low confidence); these findings were less robust to sensitivity analysis. Additionally, there was no significant difference in SGA (k = 3; moderate confidence) or preterm birth (k = 3; high confidence) between CC-exposed and ENDS-exposed neonates; these findings were robust to sensitivity analysis. Analysis of continuous outcomes found lower birthweight in ENDS- vs non-exposed neonates (k = 4; moderate confidence) and lower birthweight in CC- vs ENDS-exposed neonates (k = 4; low confidence), and no difference in gestational age in either comparison (low confidence). Narrative synthesis suggests quitting ENDS was associated with better birth outcomes, and associations between ENDS and delayed development of infant motor maturity and reflexes. Conclusion: ENDS exposure may confer comparable risk as cigarette smoking to preterm birth. Further research is needed given low to moderate confidence in findings and risk of bias conferred by limited classification of exclusive ENDS use. Implications: With respect to adverse birth outcomes, ENDS may constitute a risk compared to no-nicotine exposure, suggesting the importance of investigating vaping cessation interventions, as well as greater research into alternative smoking cessation interventions for people who are pregnant or want to become pregnant.
- 16 January 2026
- Published by BMJ in Tobacco Control
Changes in combustible cigarette and electronic nicotine delivery system use among people with and without schizophrenia spectrum disorders in the USA (2016–2023)
Background: Changes in population estimates for electronic nicotine delivery systems (ENDS) have not been investigated in people with schizophrenia-spectrum disorders (SSDs). We assess the prevalence of daily use of ENDS, cigarettes or dual use, and changes in daily use among individuals with SSDs compared with the general population. Methods: Respondents are from the Population Assessment of Tobacco and Health Study, 2016–2023 (age 18+ years) reporting (yes/no) daily combustible cigarette, daily ENDS or daily dual use at each wave (n=33 689 (517 SSD) in 2016–2017). Weighted generalised linear regression models were used to assess changes in odds of use for each product by self-reported SSD diagnosis. Results: In 2023, people with SSDs reported significantly higher rates of daily cigarette smoking (31.5%, 95% CI 28.6% to 34.4%), ENDS use (6.6%, 95% CI 5.2% to 8.0%) and dual use (1.8%, 95% CI 0.9% to 2.7%), relative to the general population (cigarettes: 10.0% (95% CI 9.7% to 10.2%); ENDS: 3.2% (95% CI 3.1% to 3.4%); dual use: 0.4% (95% CI 0.3% to 0.4%)). From 2016–2023, odds of daily cigarette smoking decreased comparably in people with and without SSDs, but remained significantly higher among people with SSDs over time. Additionally, there was an increase in the odds of ENDS use among people with (OR 1.26, 95% CI 1.11 to 1.43) and without SSDs (OR 1.07, 95% CI 1.05 to 1.10), that was comparable after adjusting for age. Odds of all three daily nicotine use patterns, as well as ENDS and cigarette dependence, were higher in people with SSDs over time. Conclusions and relevance: Despite comparable declines in daily smoking and increases in daily vaping, rates of smoking, ENDS use and dual use were persistently higher among people with SSDs, demonstrating continued nicotine/tobacco health disparities.
- 16 January 2026
- Published by BMJ in Tobacco Control
Changes in combustible cigarette and electronic nicotine delivery system use among people with and without schizophrenia spectrum disorders in the USA (2016–2023)
Background: Changes in population estimates for electronic nicotine delivery systems (ENDS) have not been investigated in people with schizophrenia-spectrum disorders (SSDs). We assess the prevalence of daily use of ENDS, cigarettes or dual use, and changes in daily use among individuals with SSDs compared with the general population. Methods: Respondents are from the Population Assessment of Tobacco and Health Study, 2016–2023 (age 18+ years) reporting (yes/no) daily combustible cigarette, daily ENDS or daily dual use at each wave (n=33 689 (517 SSD) in 2016–2017). Weighted generalised linear regression models were used to assess changes in odds of use for each product by self-reported SSD diagnosis. Results: In 2023, people with SSDs reported significantly higher rates of daily cigarette smoking (31.5%, 95% CI 28.6% to 34.4%), ENDS use (6.6%, 95% CI 5.2% to 8.0%) and dual use (1.8%, 95% CI 0.9% to 2.7%), relative to the general population (cigarettes: 10.0% (95% CI 9.7% to 10.2%); ENDS: 3.2% (95% CI 3.1% to 3.4%); dual use: 0.4% (95% CI 0.3% to 0.4%)). From 2016–2023, odds of daily cigarette smoking decreased comparably in people with and without SSDs, but remained significantly higher among people with SSDs over time. Additionally, there was an increase in the odds of ENDS use among people with (OR 1.26, 95% CI 1.11 to 1.43) and without SSDs (OR 1.07, 95% CI 1.05 to 1.10), that was comparable after adjusting for age. Odds of all three daily nicotine use patterns, as well as ENDS and cigarette dependence, were higher in people with SSDs over time. Conclusions and relevance: Despite comparable declines in daily smoking and increases in daily vaping, rates of smoking, ENDS use and dual use were persistently higher among people with SSDs, demonstrating continued nicotine/tobacco health disparities.
- Open Access
- 17 May 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (11) , 1963-1974
Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading
Introduction: Relative to other pharmacotherapies for smoking cessation, varenicline has significantly greater efficacy in females; however, sex-specific mechanisms have not yet been investigated. We conducted a secondary analysis of ecological momentary assessment data to assess whether reductions in craving, negative affect, and smoking satisfaction/reward/aversion mediate effects of varenicline on next-day smoking to a greater degree in females (n = 179) relative to males (n = 141). Aims and Methods: Data were from a 3-week medication manipulation period during the pre-quit phase of a double-blind randomized placebo-controlled trial investigating extended preloading (4 weeks) versus standard preloading of varenicline (1 week, preceded by 3 weeks of placebo, NCT03262662). Time-invariant multi-level moderated mediation models and time-varying mediation models were utilized. Results: A significant time-varying indirect effect through craving that increased in magnitude over the pre-quit period was identified only in females. Exploratory analysis found that decreases in psychological reward and smoking satisfaction mediated the relationship between varenicline and reductions in craving only in females. Time-invariant multi-level models did not evidence a significant indirect effect through candidate mediators in males or females; the index of moderated mediation was not significant in any of the models. Conclusions: Our findings suggest that the efficacy of varenicline on reductions in pre-quit smoking in females operates through reductions in craving. Furthermore, reductions in craving may be due to decreases in positive subjective experiences of smoking. Augmenting craving coping strategies as well as reducing smoking reward and satisfaction may be a beneficial approach in females. Implications: This is the first study to investigate sex-specific mediation of varenicline on reductions in pre-quit smoking. Further investigation into varenicline-induced changes in smoking reinforcement and craving is warranted, particularly in females. For example, experimentally manipulating these mediators may inform them as mechanisms for smoking reduction.
- 17 May 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 27 (11) , 1963-1974
Open AccessSex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading
Introduction: Relative to other pharmacotherapies for smoking cessation, varenicline has significantly greater efficacy in females; however, sex-specific mechanisms have not yet been investigated. We conducted a secondary analysis of ecological momentary assessment data to assess whether reductions in craving, negative affect, and smoking satisfaction/reward/aversion mediate effects of varenicline on next-day smoking to a greater degree in females (n = 179) relative to males (n = 141). Aims and Methods: Data were from a 3-week medication manipulation period during the pre-quit phase of a double-blind randomized placebo-controlled trial investigating extended preloading (4 weeks) versus standard preloading of varenicline (1 week, preceded by 3 weeks of placebo, NCT03262662). Time-invariant multi-level moderated mediation models and time-varying mediation models were utilized. Results: A significant time-varying indirect effect through craving that increased in magnitude over the pre-quit period was identified only in females. Exploratory analysis found that decreases in psychological reward and smoking satisfaction mediated the relationship between varenicline and reductions in craving only in females. Time-invariant multi-level models did not evidence a significant indirect effect through candidate mediators in males or females; the index of moderated mediation was not significant in any of the models. Conclusions: Our findings suggest that the efficacy of varenicline on reductions in pre-quit smoking in females operates through reductions in craving. Furthermore, reductions in craving may be due to decreases in positive subjective experiences of smoking. Augmenting craving coping strategies as well as reducing smoking reward and satisfaction may be a beneficial approach in females. Implications: This is the first study to investigate sex-specific mediation of varenicline on reductions in pre-quit smoking. Further investigation into varenicline-induced changes in smoking reinforcement and craving is warranted, particularly in females. For example, experimentally manipulating these mediators may inform them as mechanisms for smoking reduction.
Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial
Background and aims: Mechanisms of varenicline preloading in promoting smoking abstinence have not been evaluated. Based on an extinction of reinforcement framework, we tested the hypothesis that pre‐quit reductions in smoking rate mediate the effect of extended preloading on abstinence. We also tested alternative indicators of change in smoking reinforcement, as well as smoking aversion, nausea and abstinence self‐efficacy as candidate mediators. Design, participants and intervention: Randomized, double‐blind, placebo‐controlled trial (NCT03262662) comparing extended (4‐week varenicline) to standard (3 weeks of placebo, 1‐week varenicline) preloading, preceding 11 weeks of open‐label varenicline, in 320 adults (56% female). The primary outcome was self‐reported continuous smoking abstinence during the last 4 weeks of treatment, with cotinine bio‐verification at end of treatment (EOT). Setting: University at Buffalo, State University of New York, USA (part of the trial was conducted at participants' homes due to the COVID‐19 pandemic). Measurements: Candidate mediators, including smoking rate and subjective effects of smoking (reward, satisfaction, aversion), self‐reported craving, withdrawal, nausea and abstinence self‐efficacy, were assessed daily during the pre‐quit period with ecological momentary assessment. At two laboratory visits participants completed a choice task to assess smoking reinforcement. Findings: There was a statistically significant indirect effect of extended preloading on greater EOT abstinence rates through pre‐quit declines in smoking rate [ a*b = 0.284, 95% confidence interval (0.072,0.616)] and percent reduction in smoking across the pre‐quit period [ a*b = 0.225, (0.080,0.437)]. There were also statistically significant indirect effects through reductions in pre‐quit craving [ a*b = 0.150, (0.01,0.420)] and increases in pre‐quit self‐efficacy [ a*b = 0.157, (0.038,0.375)]. Sex‐specific analyses suggested these mediated effects were consistently limited to females. No other candidate mediators yielded statistically significant indirect effects. Conclusions: Extended varenicline preloading mediated smoking abstinence through reduced pre‐quit smoking and craving among female smokers seeking to quit; increased pre‐quit abstinence self‐efficacy was also a significant mediator.
Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial
Background and aims: Mechanisms of varenicline preloading in promoting smoking abstinence have not been evaluated. Based on an extinction of reinforcement framework, we tested the hypothesis that pre‐quit reductions in smoking rate mediate the effect of extended preloading on abstinence. We also tested alternative indicators of change in smoking reinforcement, as well as smoking aversion, nausea and abstinence self‐efficacy as candidate mediators. Design, participants and intervention: Randomized, double‐blind, placebo‐controlled trial (NCT03262662) comparing extended (4‐week varenicline) to standard (3 weeks of placebo, 1‐week varenicline) preloading, preceding 11 weeks of open‐label varenicline, in 320 adults (56% female). The primary outcome was self‐reported continuous smoking abstinence during the last 4 weeks of treatment, with cotinine bio‐verification at end of treatment (EOT). Setting: University at Buffalo, State University of New York, USA (part of the trial was conducted at participants' homes due to the COVID‐19 pandemic). Measurements: Candidate mediators, including smoking rate and subjective effects of smoking (reward, satisfaction, aversion), self‐reported craving, withdrawal, nausea and abstinence self‐efficacy, were assessed daily during the pre‐quit period with ecological momentary assessment. At two laboratory visits participants completed a choice task to assess smoking reinforcement. Findings: There was a statistically significant indirect effect of extended preloading on greater EOT abstinence rates through pre‐quit declines in smoking rate [ a*b = 0.284, 95% confidence interval (0.072,0.616)] and percent reduction in smoking across the pre‐quit period [ a*b = 0.225, (0.080,0.437)]. There were also statistically significant indirect effects through reductions in pre‐quit craving [ a*b = 0.150, (0.01,0.420)] and increases in pre‐quit self‐efficacy [ a*b = 0.157, (0.038,0.375)]. Sex‐specific analyses suggested these mediated effects were consistently limited to females. No other candidate mediators yielded statistically significant indirect effects. Conclusions: Extended varenicline preloading mediated smoking abstinence through reduced pre‐quit smoking and craving among female smokers seeking to quit; increased pre‐quit abstinence self‐efficacy was also a significant mediator.
- 1 April 2024
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 32 (2) , 236-244
Stereotype threat contributes to poorer recall performance among undergraduate students with problematic drinking patterns.
Stereotype threat occurs when individuals from stigmatized groups feel they are expected to conform to a negative stereotype associated with their group. Studies show that activating stereotype threat can impair performance on cognitive tasks in various marginalized groups. Individuals with problematic alcohol use are subject to stigmatized views related to cognitive abilities and socialization skills; thus, we examine for the first time whether eliciting stereotype threat impairs performance on a memory and a theory of mind task in undergraduate students with varying drinking patterns. We randomized 205 students to a neutral or a stereotype threat condition, which informed participants that the purpose of the study was to assess memory performance and theory of mind skills in relation to different patterns of alcohol consumption. In the stereotype threat group, individuals with problematic drinking patterns demonstrated significantly worse memory performance than nonproblematic drinkers and nondrinkers. The same was not true in the neutral condition, where memory recall did not differ significantly as a function of drinking status. Experimental group and drinking status failed to reveal significant effects on cognitive and affective theory of mind performance. Problematic alcohol use patterns were only associated with poorer memory when stereotype threat was elicited, which indicates that assessments of neurocognitive profiles may be biased, at least for memory performance, if stereotype threat is inadvertently elicited in substance users. Broader implications support the imperative to avoid stigmatization of problematic substance use in scientific communication and clinical settings.
- 1 April 2024
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 32 (2) , 236-244
Stereotype threat contributes to poorer recall performance among undergraduate students with problematic drinking patterns.
Stereotype threat occurs when individuals from stigmatized groups feel they are expected to conform to a negative stereotype associated with their group. Studies show that activating stereotype threat can impair performance on cognitive tasks in various marginalized groups. Individuals with problematic alcohol use are subject to stigmatized views related to cognitive abilities and socialization skills; thus, we examine for the first time whether eliciting stereotype threat impairs performance on a memory and a theory of mind task in undergraduate students with varying drinking patterns. We randomized 205 students to a neutral or a stereotype threat condition, which informed participants that the purpose of the study was to assess memory performance and theory of mind skills in relation to different patterns of alcohol consumption. In the stereotype threat group, individuals with problematic drinking patterns demonstrated significantly worse memory performance than nonproblematic drinkers and nondrinkers. The same was not true in the neutral condition, where memory recall did not differ significantly as a function of drinking status. Experimental group and drinking status failed to reveal significant effects on cognitive and affective theory of mind performance. Problematic alcohol use patterns were only associated with poorer memory when stereotype threat was elicited, which indicates that assessments of neurocognitive profiles may be biased, at least for memory performance, if stereotype threat is inadvertently elicited in substance users. Broader implications support the imperative to avoid stigmatization of problematic substance use in scientific communication and clinical settings.
- 30 January 2024
- Published by Elsevier in Addictive Behaviors
- Vol. 152, 107978
Distal and proximal risk factors of problematic cannabis use associated with psychotic-like experiences
- 30 January 2024
- Published by Elsevier in Addictive Behaviors
- Vol. 152, 107978
Distal and proximal risk factors of problematic cannabis use associated with psychotic-like experiences
- 2 January 2024
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 50 (1) , 95-105
Cannabis cravings predict cigarette use in schizophrenia: a secondary analysis from two cannabis abstinence studies
- 2 January 2024
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 50 (1) , 95-105
Cannabis cravings predict cigarette use in schizophrenia: a secondary analysis from two cannabis abstinence studies
- 6 December 2023
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 254, 111054
Endorsement of psychotic-like experiences and problematic cannabis use associated with worse executive functioning performance in undergraduates
- 6 December 2023
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 254, 111054
Endorsement of psychotic-like experiences and problematic cannabis use associated with worse executive functioning performance in undergraduates
- Open Access
- 25 August 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (8) , 696-706
A Systematic Review of Pharmacological Treatments for Internet Gaming Disorder
Objective Internet gaming disorder (IGD) is an increasingly common behavioral addiction, with an estimated global prevalence of 3%. A variety of pharmacological treatments have been used to treat IGD, yet no review to date has synthesized clinical trials evaluating their efficacy. This systematic review therefore synthesized the literature reporting on clinical trials of pharmacological treatments for IGD.Methods We reviewed articles from MEDLINE, Embase, PubMed Central, CINAHL, and PsycINFO that were published as of March of 2022. A total of 828 articles were retrieved for review and 12 articles were included, reporting on a total of 724 participants.Results Most participants were male (98.6%), and all were currently living in South Korea. The most common drugs used to treat IGD were bupropion, methylphenidate, and a range of selective serotonin reuptake inhibitors. The Young Internet Addiction Scale was the most frequently used to measure gaming-related outcomes. All studies reported reduced symptoms of IGD from pre- to post-treatment. Across all clinical trials, IGD symptom reductions following the administration of pharmacological treatments ranged from 15.4% to 51.4%. A risk of bias assessment indicated that only four studies had a low risk of bias.Conclusion Preliminary results suggest that a wide array of pharmacological interventions may be efficacious in the treatment of IGD. Future studies using double-blind randomized controlled trial designs, recruiting larger and more representative samples, and controlling for psychiatric comorbidities are needed to better inform understanding of pharmacological treatments for IGD.
- 25 August 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (8) , 696-706
Open AccessA Systematic Review of Pharmacological Treatments for Internet Gaming Disorder
Objective Internet gaming disorder (IGD) is an increasingly common behavioral addiction, with an estimated global prevalence of 3%. A variety of pharmacological treatments have been used to treat IGD, yet no review to date has synthesized clinical trials evaluating their efficacy. This systematic review therefore synthesized the literature reporting on clinical trials of pharmacological treatments for IGD.Methods We reviewed articles from MEDLINE, Embase, PubMed Central, CINAHL, and PsycINFO that were published as of March of 2022. A total of 828 articles were retrieved for review and 12 articles were included, reporting on a total of 724 participants.Results Most participants were male (98.6%), and all were currently living in South Korea. The most common drugs used to treat IGD were bupropion, methylphenidate, and a range of selective serotonin reuptake inhibitors. The Young Internet Addiction Scale was the most frequently used to measure gaming-related outcomes. All studies reported reduced symptoms of IGD from pre- to post-treatment. Across all clinical trials, IGD symptom reductions following the administration of pharmacological treatments ranged from 15.4% to 51.4%. A risk of bias assessment indicated that only four studies had a low risk of bias.Conclusion Preliminary results suggest that a wide array of pharmacological interventions may be efficacious in the treatment of IGD. Future studies using double-blind randomized controlled trial designs, recruiting larger and more representative samples, and controlling for psychiatric comorbidities are needed to better inform understanding of pharmacological treatments for IGD.